ProKidney Corp. (PROK) Stock Analysis

What ProKidney Corp. does

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Key metrics

ETFs linked to PROK

Broad-market and Healthcare sector ETFs an investor holding ProKidney Corp. is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PROK fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for ProKidney Corp.?

ProKidney Corp. trades under the ticker PROK on NASDAQ.

Which exchange is PROK listed on?

PROK is listed on NASDAQ.

What sector does ProKidney Corp. operate in?

ProKidney Corp. is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PROK in a portfolio?

PortView shows PROK's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.